Procalcitonin and community-acquired pneumonia (CAP) in children
- Authors: Bivona, G; Agnello, L; Scazzone, C; Lo Sasso, B; Bellia, C; Ciaccio, M
- Publication year: 2015
- Type: Articolo in rivista (Articolo in rivista)
- Key words: Biomarkers; Children; Community-acquired pneumonia; PCT; Pediatric CAP; Procalcitonin
- OA Link: http://hdl.handle.net/10447/157128
Abstract
The role of procalcitonin (PCT) as a biomarker for sepsis in adults is well documented, while its role in infections affecting neonatal children remains controversial. Among these infections, Community-Acquired pneumonia (CAP) has been studied extensively, because it's the second cause of death in children in developing countries, and one of the most frequent causes of hospitalization in industrialized countries. The PubMed database and the Cochrane Library were used to search for the following keywords: CAP, procalcitonin, children. Thirteen articles were studied to determine the role of PCT in CAP management, specifically its usefulness for distinguishing pneumococcal infections from viral and unknown infections, for predicting severity and the correct antibiotic treatment. This paper focuses on the studies performed to identify the best inflammatory biomarker for CAP management. Although there is an increase in studies confirming the usefulness of PCT in CAP management in children, further studies are needed to have better understanding of its role for pediatric CAP management.